RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mithra Pharmaceuticals Stock

Mithra Pharmaceuticals P/E 2024

Mithra Pharmaceuticals P/E

-0.65

Ticker

MITRA.BR

ISIN

BE0974283153

WKN

A14V4E

As of Oct 4, 2024, Mithra Pharmaceuticals's P/E ratio was -0.65, a -28.57% change from the -0.91 P/E ratio recorded in the previous year.

The Mithra Pharmaceuticals P/E history

Mithra Pharmaceuticals Aktienanalyse

What does Mithra Pharmaceuticals do?

Mithra Pharmaceuticals SA is a Belgian pharmaceutical company specializing in women's health and hormone therapy. The company was founded in 1999 by François Fornieri and Jean-Michel Foidart and has since become a major player in women's healthcare. Its unique business model covers the entire value chain of the pharmaceutical industry, including research and development, production, distribution, and marketing of its own products. Mithra Pharmaceuticals SA collaborates with other pharmaceutical companies, universities, and public research institutions worldwide, aiming to offer innovative products and services based on new technologies and scientific knowledge. The company's divisions include hormone therapy, contraception, gynecology, and dermatology, providing a wide range of products and services tailored to women's needs. One of its notable products is the Estetrol patch, a safe and effective contraceptive containing a natural estrogen hormone produced during pregnancy. In gynecology, Mithra Pharmaceuticals SA offers products for the treatment of menstrual disorders, endometriosis, and vaginal dryness, such as the Estelle pill concept, which combines contraception and hormone regulation. In dermatology, the company provides skincare products based on natural ingredients, specifically designed for women with sensitive skin or skin issues. Overall, Mithra Pharmaceuticals SA focuses on meeting the needs of women and has a history of adapting to market conditions and offering innovative products and services. With its global presence and innovative products, Mithra Pharmaceuticals SA is well-positioned for future success. Mithra Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Mithra Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Mithra Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Mithra Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Mithra Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Mithra Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Mithra Pharmaceuticals stock

What is the price-to-earnings ratio of Mithra Pharmaceuticals?

The price-earnings ratio of Mithra Pharmaceuticals is currently -0.65.

How has the price-earnings ratio of Mithra Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Mithra Pharmaceuticals has increased by -28.57% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Mithra Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Mithra Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Mithra Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Mithra Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Mithra Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Mithra Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Mithra Pharmaceuticals?

Some factors that influence the price-earnings ratio of Mithra Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Mithra Pharmaceuticals pay?

Over the past 12 months, Mithra Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mithra Pharmaceuticals is expected to pay a dividend of 0 EUR.

What is the dividend yield of Mithra Pharmaceuticals?

The current dividend yield of Mithra Pharmaceuticals is .

When does Mithra Pharmaceuticals pay dividends?

Mithra Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mithra Pharmaceuticals?

Mithra Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Mithra Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mithra Pharmaceuticals located?

Mithra Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mithra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mithra Pharmaceuticals from 10/4/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Mithra Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Mithra Pharmaceuticals in the year 2023?

In the year 2023, Mithra Pharmaceuticals distributed 0 EUR as dividends.

In which currency does Mithra Pharmaceuticals pay out the dividend?

The dividends of Mithra Pharmaceuticals are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mithra Pharmaceuticals

Our stock analysis for Mithra Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mithra Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.